Form 4: Director Cathy Friedman Receives Lyell Immunopharma Options

Lyell Immunopharma director Cathy Friedman was granted 9,250 stock options as part of standard equity compensation.

Summary

• Director Cathy Friedman was granted 9,250 stock options to purchase common stock at an exercise price of $13.22.
• The grant occurred on June 10, 2026, with an expiration date of June 9, 2036.
• The filing confirms the reporting person maintains indirect beneficial ownership in the Duane Family Trust and The Duane Irrevocable Trust 2020.
• All share counts reflect the 1-for-20 reverse stock split effected on May 30, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a routine disclosure of director compensation.

Risks

• The value of the granted options is dependent on the future market performance of Lyell Immunopharma common stock.

Future Outlook

The options vest on the earlier of the next annual meeting of stockholders following June 10, 2026, or the first anniversary of the grant date, contingent upon continuous service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to incentivize board members and align their interests with long-term corporate performance.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard corporate governance practices for mid-cap and small-cap biotech firms.
• The vesting schedule tied to annual meetings is a common retention mechanism for board members in the industry.

Related Party Transactions

• Reporting person maintains indirect beneficial ownership in the Duane Family Trust and The Duane Irrevocable Trust 2020.

Stakeholder Impact

• Minimal impact on shareholders; reflects standard board compensation.

Next Steps

• Vesting of options on the earlier of the next annual meeting or June 10, 2027.

Key Dates

Keywords

Lyell Immunopharma, LYEL, Form 4, Director Compensation, Stock Options, Insider Trading, Biotech